About Us
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer.
-
Non Regulatory July 1, 2024Vivesto receives positive Cantrixil preclinical efficacy data
-
Regulatory May 23, 2024Report from Annual General Meeting in Vivesto AB
-
Regulatory April 23, 2024Notice of Annual General Meeting in Vivesto AB
Interim Report Q1 2024
Vivesto published its Q1 report for 2024 on May 23, 2024, at 08.00 am CEST.
(in Swedish)